phrykt

Elevance Health, Inc. (ELV): who owns it and who trades it

As of Nov 16, 2026, ELV insiders reported 19 open-market sales worth $7M and 4 purchases worth $2.2M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mark Kaye (CFO), with $4.7M. 10 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Elevance Health

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, ELV insiders reported $2.2M of open-market purchases and $7M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$2.2M
4 trades, 3 people
Sales, 12 months
$7M
19 trades, 6 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 5, 2026
Filed Nov 6, 2026

Purchases and sales by month

$4.7M$4.7MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 5, 2026Ratnakar LavuVice presidentSale1,300$440.00$572KForm 4
Oct 22, 2026Mark KayeCFOSale400$434.00$174KForm 4
Oct 22, 2026Mark KayeCFOSale321$435.25$140KForm 4
Oct 22, 2026Mark KayeCFOSale1,660$436.20$724KForm 4
Oct 22, 2026Mark KayeCFOSale560$437.07$245KForm 4
Oct 22, 2026Mark KayeCFOSale240$438.22$105KForm 4
Oct 22, 2026Mark KayeCFOSale1,160$439.25$510KForm 4
Oct 22, 2026Mark KayeCFOSale1,720$440.44$758KForm 4
Oct 22, 2026Mark KayeCFOSale2,343$441.34$1MForm 4
Oct 22, 2026Mark KayeCFOSale480$442.61$212KForm 4
Oct 22, 2026Mark KayeCFOSale440$443.81$195KForm 4
Oct 22, 2026Mark KayeCFOSale160$444.85$71.2KForm 4
Oct 22, 2026Mark KayeCFOSale827$446.05$369KForm 4
Oct 22, 2026Mark KayeCFOSale273$447.19$122KForm 4
Jul 17, 2026Ramiro G PeruDirectorPurchase1,000$366.05$366KForm 4
Jul 17, 2026Gail BoudreauxCEOPurchase680$366.41$249KForm 4
Jul 17, 2026Gail BoudreauxCEOPurchase2,045$368.25$753KForm 4
Jun 12, 2026Ronald W PenczekCAO & ControllerSale369$403.16$149KForm 4
Jun 11, 2026Robert L Dixon JRDirectorSale151$401.77$60.7KForm 4
May 19, 2026Ronald W PenczekCAO & ControllerSale1,531$403.13$617KForm 4
Mar 12, 2026Amy W SchulmanDirectorSale26$287.50$7.5KForm 4
Mar 6, 2026Charles Morgan Kendrick JRVice presidentSale3,196$284.92$911KForm 4
Mar 5, 2026Steven H CollisDirectorPurchase3,000$289.84$870KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Mark KayeEVP & CFO–$4.7MOct 22, 2026
Gail BoudreauxPresident and CEO, Director$1M–Jul 17, 2026
Charles Morgan Kendrick JREVP & President, Commercial–$911KMar 6, 2026
Steven H CollisDirector$870K–Mar 5, 2026
Ronald W PenczekCAO & Controller–$766KJun 12, 2026
Ratnakar LavuEVP & Chief Digital Info Ofr–$572KNov 5, 2026
Ramiro G PeruDirector$366K–Jul 17, 2026
Robert L Dixon JRDirector–$60.7KJun 11, 2026
Amy W SchulmanDirector–$7.5KMar 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ELV short interest

Low short interest. 2.1% of ELV shares are sold short: about 1 share in 48. Over the last 12 reports the number of shares short went down 26%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.54M ELV shares were sold short, 2.1% of the shares outstanding, down 11.5% from the report before. At the average daily volume of 1.39M shares, buying them all back would take about 3.3 trading days (days to cover).

Shares short, % of all shares

2.10%May 15Oct 303.18%

Days to cover

3.3May 15Oct 307.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.54M2.10%-12%1.39M3.3
Oct 15, 20265.14M2.38%+6%1.29M4.0
Sep 30, 20264.85M2.24%-9%1.24M3.9
Sep 15, 20265.34M2.46%-3%1.27M4.2
Aug 31, 20265.49M2.53%+1%836,6856.6
Aug 14, 20265.41M2.49%-3%952,8315.7
Jul 31, 20265.59M2.58%-7%1.42M3.9
Jul 15, 20266.03M2.78%+0%1.71M3.5
Jun 30, 20266.01M2.77%-4%1.84M3.3
Jun 15, 20266.28M2.89%-5%1.79M3.5
May 29, 20266.60M3.04%+8%1.52M4.3
May 15, 20266.10M2.81%+18%1.66M3.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded ELV

Since Nov 17, 2024, 8 members of Congress reported 6 purchases and 9 sales of ELV. The latest was a purchase by Alan Armstrong on Mar 27, 2026, reported Jul 21, 2026.

Purchases 6Sales 9

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Mar 27, 2026Alan Armstrong (R-OK)Purchase$1K–$15KSelfJul 21, 2026Report
Aug 13, 2025Lisa C. McClain (R-MI)Sale$1K–$15KSpouseSep 12, 2025Report
Aug 5, 2025Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfSep 12, 2025Report
Jul 10, 2025Lisa C. McClain (R-MI)Purchase$1K–$15KSpouseAug 13, 2025Report
Jun 24, 2025Lisa C. McClain (R-MI)Purchase$1K–$15KSpouseAug 13, 2025Report
May 30, 2025Gilbert Ray Cisneros, Jr. (D-CA)Sale$1K–$15KSelfJun 6, 2025Report
May 15, 2025Robert P. Bresnahan, Jr. (R-PA)Sale$15K–$50KSelfMay 31, 2025Report
May 12, 2025Jefferson Shreve (R-IN)Sale$15K–$50KSelfJun 22, 2025Report
Apr 29, 2025Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfMay 6, 2025Report
Apr 11, 2025Dan Newhouse (R-WA)Partial sale$1K–$15KSpouseMay 16, 2025Report
Mar 10, 2025Jared Moskowitz (D-FL)Sale$1K–$15KChildApr 8, 2025Report
Mar 10, 2025Jared Moskowitz (D-FL)Sale$1K–$15KSelfApr 8, 2025Report
Feb 24, 2025Jefferson Shreve (R-IN)Purchase$15K–$50KSelfMar 9, 2025Report
Jan 13, 2025Val T. Hoyle (D-OR)Sale$1K–$15KSpouseSep 12, 2025Report
Jan 13, 2025Robert P. Bresnahan, Jr. (R-PA)Sale$1K–$15KJointFeb 13, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Elevance Health company events

Elevance Health filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026AnnouncementShared information with investors. Filing
  2. Oct 21, 2026ResultsReleased financial results. Filing
  3. Sep 10, 2026AnnouncementShared information with investors. Filing
  4. Jul 15, 2026ResultsReleased financial results. Filing
  5. Jun 10, 2026AnnouncementShared information with investors. Filing
  6. May 13, 2026VoteReported shareholder vote results. Filing
  7. Apr 22, 2026ResultsReleased financial results. Filing
  8. Mar 10, 2026AnnouncementShared information with investors. Filing
  9. Mar 2, 2026AnnouncementElevance Health, Inc. was notified by the Centers for Medicare & Medicaid Services of its intent to impose intermediate sanctions suspending enrollment of Medicare beneficiaries into the Company’s Medicare Advantage-Prescription Drug plans and suspending certain communication activities to Medicare… Filing
  10. Feb 26, 2026LeadershipElevance Health, Inc. announced certain management changes. Filing
  11. Jan 28, 2026ResultsReleased financial results. Filing
  12. Dec 10, 2025LeadershipThe Board of Directors of Elevance Health, Inc. elected Amy W. Schulman to serve as an independent director effective January 12, 2026, with a term expiring at the Company’s 2028 annual meeting of shareholders. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Elevance Health financials

Famous investors that hold ELV

10 of the 50 well-known investors we track reported holding ELV in their latest 13F filing. The largest position is Bill Nygren's, worth $1.9B.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Bill Nygren · Harris Associates (Oakmark)Q3 20264.78M$1.9B2.4%-3%
Jeremy Grantham · GMOQ3 20261.68M$653M1.4%-1%
Seth Klarman · Baupost GroupQ3 20261.28M$496M9.8%No change
Glenn Greenberg · Brave Warrior AdvisorsQ3 2026579,472$225M5.2%-41%
Ken Griffin · Citadel AdvisorsQ3 2026388,335$151M0.1%-57%
Jim Simons · Renaissance TechnologiesQ3 2026322,613$125M0.2%+60%
Richard Pzena · Pzena Investment ManagementQ3 2026233,128$90.6M0.3%+4%
Israel Englander · Millennium ManagementQ3 20263,926$1.5M0.0%-99%
Lee Ainslie · Maverick CapitalQ3 20263,465$1.3M0.0%New
Ken Fisher · Fisher Asset ManagementQ3 20261,660$646K0.0%+3%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Elevance Health, Inc. (ELV) stock

Are ELV insiders buying or selling?

In the last 12 months, ELV insiders reported 4 open-market purchases worth $2.2M and 19 sales worth $7M. The latest trade was on Nov 5, 2026. See every trade.

What is the short interest in ELV?

As of Oct 30, 2026, 4.54M ELV shares were sold short, 2.1% of the shares outstanding, down 11.5% from the report before. At the average daily volume of 1.39M shares, buying them all back would take about 3.3 trading days (days to cover). See the history.

Have members of Congress traded ELV?

Yes. 8 members of Congress reported 6 purchases and 9 sales of ELV since Nov 17, 2024. The latest was reported on Jul 21, 2026. See the trades.

Which famous investors hold ELV?

10 of the 50 well-known investors we track reported ELV in their latest 13F filing, including Bill Nygren, Jeremy Grantham, Seth Klarman. The largest position is worth $1.9B. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.